Mevion Medical Systems has partnered with Nebraska Medicine to install a proton therapy system at the Fred & Pamela Buffett Cancer Center in Omaha, Nebraska, US.
The MEVION S250-FIT proton therapy system will be incorporated into an existing treatment room within the cancer centre's radiation oncology department.
The cancer centre is among the first to adopt the MEVION S250-FIT technology alongside other healthcare providers such as BayCare, Stanford Health Care and Atlantic Health.
Its installation of the proton therapy system is part of Nebraska Medicine's efforts to offer advanced cancer treatment options in a single, accessible location.
Nebraska Medicine CEO and board chair Dr James Linder said: “Nebraska Medicine is committed to providing our patients with the most advanced cancer care available.
“The support of the donor community has enabled the addition of proton therapy to the Fred & Pamela Buffett Cancer Center, and marks another important step in fulfilling that commitment.”
Mevion Medical Systems president and CEO Tina Yu said: “We are excited to partner with Nebraska Medicine to make proton therapy more accessible to their patients.
“The MEVION S250-FIT represents a major advancement in proton therapy accessibility and affordability, and we are proud to collaborate with Nebraska Medicine in their mission to provide world-class treatment options.”
The MEVION S250-FIT system's compact size, precise pencil beam scanning and upright patient positioning are expected to 'revolutionise' cancer care at the institution.
Its precision could be particularly useful for treating paediatric patients and targeting tumours in sensitive areas, as it offers the potential to reduce damage to healthy surrounding tissue.
Fred & Pamela Buffett Cancer Center director Dr Joann Sweasy said: “This advanced proton therapy system opens doors for us to explore new frontiers in cancer treatment, including FLASH therapy and other innovative approaches.
“We are committed to pushing the boundaries of proton therapy research and bringing the latest advancements to the clinic.”
